MDB Capital Holdings, LLC (NASDAQ:MDBH – Get Free Report) saw a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 2,107 shares, a drop of 68.9% from the January 15th total of 6,782 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 9,238 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 9,238 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are sold short.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d)” rating on shares of MDB Capital in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on MDBH
Hedge Funds Weigh In On MDB Capital
MDB Capital Trading Up 2.7%
Shares of MDBH stock traded up $0.09 during mid-day trading on Wednesday, reaching $3.19. The stock had a trading volume of 11,447 shares, compared to its average volume of 8,044. The firm has a market capitalization of $32.30 million, a PE ratio of 3.42 and a beta of 1.09. The stock’s 50-day moving average price is $3.39 and its two-hundred day moving average price is $3.55. MDB Capital has a 52-week low of $3.00 and a 52-week high of $7.98.
MDB Capital (NASDAQ:MDBH – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.46) earnings per share for the quarter. The firm had revenue of $1.42 million for the quarter.
MDB Capital Company Profile
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.
See Also
- Five stocks we like better than MDB Capital
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for MDB Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDB Capital and related companies with MarketBeat.com's FREE daily email newsletter.
